Patients who undergo autologous hematopoietic stem cell transplantation (aHCT) for treatment of a relapsed or refractory lymphoma are at risk of developing therapy related- myelodysplasia/acute myeloid leukemia (t-MDS/AML). Part of the risk likely resides in inherent interindividual differences in their DNA repair capacity (DRC), which is thought to influence the effect chemotherapeutic treatments have on the patient's stem cells prior to aHCT. Measuring DRC involves identifying small differences in repair proficiency among individuals. Initially, we investigated the cell model in healthy individuals (primary lymphocytes and/or lymphoblastoid cell lines) that would be appropriate to measure genetically determined DRC using host-cell reactiv...
pacity may influence cancer risk. We tested whether the nucleotide excision repair pathway was defic...
Whereas transformation events in hematopoietic malignancies may occur at different developmental sta...
Myelodysplastic syndromes (MDS) are a heterogeneous group of diseases characterized by blood cytopen...
Patients who undergo autologous hematopoietic stem cell transplantation (aHCT) for treatment of a re...
<div><p>Patients who undergo autologous hematopoietic stem cell transplantation (aHCT) for treatment...
<div><p>Patients who develop therapy-related myelodysplasia/acute myeloid leukemia after autologous-...
Patients who develop therapy-related myelodysplasia/acute myeloid leukemia after autologous-hematopo...
We investigated whether early lymphocyte recovery, after unmanipulated, haploidentical, blood and ma...
Acute myeloid leukaemia (AML) is a heterogeneous myeloid malignancy characterized by clonal expansio...
Minimal residual disease (MRD) quantification is an important predictor of outcome after treatment f...
Cell therapy is presently a treatment of choice for many types of haematological and metabolic disea...
Autologous bone marrow (BM) transplantation for acute myeloid leukaemia (AML) in complete remission ...
Hematopoietic stem cells (HSCs) are responsible for sustaining hematopoietic homeostasis and regener...
Summary: Clonal hematopoiesis of indeterminate potential (CHIP) is caused by recurrent somatic mutat...
We studied acute myeloid leukemia (AML) patients with lympho-myeloid clonal hematopoiesis (LM-CH), d...
pacity may influence cancer risk. We tested whether the nucleotide excision repair pathway was defic...
Whereas transformation events in hematopoietic malignancies may occur at different developmental sta...
Myelodysplastic syndromes (MDS) are a heterogeneous group of diseases characterized by blood cytopen...
Patients who undergo autologous hematopoietic stem cell transplantation (aHCT) for treatment of a re...
<div><p>Patients who undergo autologous hematopoietic stem cell transplantation (aHCT) for treatment...
<div><p>Patients who develop therapy-related myelodysplasia/acute myeloid leukemia after autologous-...
Patients who develop therapy-related myelodysplasia/acute myeloid leukemia after autologous-hematopo...
We investigated whether early lymphocyte recovery, after unmanipulated, haploidentical, blood and ma...
Acute myeloid leukaemia (AML) is a heterogeneous myeloid malignancy characterized by clonal expansio...
Minimal residual disease (MRD) quantification is an important predictor of outcome after treatment f...
Cell therapy is presently a treatment of choice for many types of haematological and metabolic disea...
Autologous bone marrow (BM) transplantation for acute myeloid leukaemia (AML) in complete remission ...
Hematopoietic stem cells (HSCs) are responsible for sustaining hematopoietic homeostasis and regener...
Summary: Clonal hematopoiesis of indeterminate potential (CHIP) is caused by recurrent somatic mutat...
We studied acute myeloid leukemia (AML) patients with lympho-myeloid clonal hematopoiesis (LM-CH), d...
pacity may influence cancer risk. We tested whether the nucleotide excision repair pathway was defic...
Whereas transformation events in hematopoietic malignancies may occur at different developmental sta...
Myelodysplastic syndromes (MDS) are a heterogeneous group of diseases characterized by blood cytopen...